Document Detail


Ramipril: a review of its use in the prevention of cardiovascular outcomes.
MedLine Citation:
PMID:  12076194     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSION: Ramipril 10 mg/day can significantly reduce the incidence of MI, stroke or death from cardiovascular causes in patients aged > or =55 years who are at increased risk for the development of ischaemic cardiovascular events due to a history of stroke, coronary artery disease (with controlled blood pressure), diabetes mellitus plus at least one other risk factor or peripheral vascular disease but no heart failure or low ejection fraction. Therefore, in addition to dietary and lifestyle modifications, ramipril should be an integral part of secondary prevention therapy in patients at increased risk for the development of cardiovascular events.
Authors:
Gregory T Warner; Caroline M Perry
Related Documents :
12778024 - Contrast echocardiography using intravenous octafluoropropane and real-time perfusion i...
16205944 - Immunohistochemical expression of activated caspase-3 in human myocardial infarction.
11773914 - Incidence of high-risk acute coronary syndromes and eligibility for glycoprotein iib/ii...
24813354 - Consideration of qrs complex in addition to st-segment abnormalities in the estimation ...
21159804 - Right heart dilatation in adult congenital heart disease: imaging appearance on cardiac...
1955684 - Evaluation of a mobile coronary care unit protocol in patients with acute onset chest p...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  62     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2002  
Date Detail:
Created Date:  2002-06-21     Completed Date:  2002-08-19     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  1381-405     Citation Subset:  IM    
Affiliation:
Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Animals
Cardiovascular Diseases / drug therapy*
Disease Progression
Humans
Ramipril / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 87333-19-5/Ramipril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Perindopril: in congestive heart failure.
Next Document:  Enoxaparin: an update of its clinical use in the management of acute coronary syndromes.